Prognostic modelling in ischaemic stroke study, additional value of genetic characteristics: Rationale and design

European Neurology

Volumn 59, Issue 5, 2008, Pages 243-252

  Achterberg, S ^a,b   Kappelle, L J ^a   Algra, A ^a,b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Antithrombotics; Genetics; Haemorrhages; Ischaemic stroke, prognosis; Pharmacogenetics; Secondary prevention

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ALPHA2 INTEGRIN; BETA1 INTEGRIN; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8A; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYTOCHROME P450 2C9; FIBRINOGEN; FIBRINOGEN BETA; FIBRINOGEN GAMMA; GLYCOPROTEIN IB ALPHA; GLYCOPROTEIN IIIA; GLYCOPROTEIN VI; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN; THROMBOPLASTIN; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE COMPLEX 1; VON WILLEBRAND FACTOR;

AMINO ACID SUBSTITUTION; ANTICIPATION; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; FOLLOW UP; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; HAPLOTYPE; HEMOSTASIS; HUMAN; MAJOR CLINICAL STUDY; MODEL; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; ROC CURVE; STROKE PATIENT;

HAPLOTYPES; HEMOSTASIS; HUMANS; POLYMORPHISM, GENETIC; PROGNOSIS; RESEARCH DESIGN; RISK FACTORS; ROC CURVE; STROKE;

EID: 42449141136     PISSN: 00143022     EISSN: None     Source Type: Journal    
DOI: 10.1159/000115638     Document Type: Article

References (77)

1. Dippel DW, Koudstaal PJ; Dutch TIA Trial Study Group: We need stronger predictors of major vascular events in patients with a recent transient ischemic attack or nondisabling stroke. Stroke 1997;28:774-776.
2. Szolnoki Z, Melegh B: Gene-gene and gene-environment interplay represent specific susceptibility for different types of ischaemic stroke and leukoaraiosis. Curr Med Chem 2006;13:1627-1634.
3. Hassan A, Markus HS: Genetics and ischaemic stroke. Brain 2000;123:1784-1812.
4. Kappelle LJ, van Latum JC, van Swieten JC, Algra A, Koudstaal PJ, van Gijn J; Dutch TIA Trial Study Group: Recurrent stroke after transient ischaemic attack or minor ischaemic stroke: does the distinction between small and large vessel disease remain true to type? J Neurol Neurosurg Psychiatry 1995;59:127-131.
5. De Jong G, Van Raak L, Kessels F, Lodder J: Stroke subtype and mortality: a follow-up study in 998 patients with a first cerebral infarct. J Clin Epidemiol 2003;56:262-268.
6. Pruissen DM, Gerritsen SA, Prinsen TJ, Dijk JM, Kappelle LJ, Algra A: Carotid intimamedia thickness is different in large- and small-vessel ischemic stroke: the SMART study. Stroke 2007;38:1371-1373.
7. Elbaz A, Poirier O, Canaple S, Chedru F, Cambien F, Amarenco P: The association between the Val34Leu polymorphism in the factor XIII gene and brain infarction. Blood 2000;95:586-591.
8. Reiner AP, Frank MB, Schwartz SM, Linenberger ML, Longstreth WT, Teramura G, Rosendaal FR, Psaty BM, Siscovick DS: Coagulation factor XIII polymorphisms and the risk of myocardial infarction and ischaemic stroke in young women. Br J Haematol 2002;116:376-382.
9. Reiner AP, Heckbert SR, Vos HL, Ariens RA, Lemaitre RN, Smith NL, Lumley T, Rea TD, Hindorff LA, Schellenbaum GD, Rosendaal FR, Siscovick DS, Psaty BM: Genetic variants of coagulation factor XIII, postmenopausal estrogen therapy, and risk of nonfatal myocardial infarction. Blood 2003;102:25-30.
10. Komanasin N, Catto AJ, Futers TS, van Hylckama V, Rosendaal FR, Ariens RA: A novel polymorphism in the factor XIII B-subunit (His95Arg): relationship to subunit dissociation and venous thrombosis. J Thromb Haemost 2005;3:2487-2496.
11. Reiner AP, Schwartz SM, Frank MB, Longstreth WT Jr, Hindorff LA, Teramura G, Rosendaal FR, Gaur LK, Psaty BM, Siscovick DS: Polymorphisms of coagulation factor XIII subunit A and risk of nonfatal hemorrhagic stroke in young white women. Stroke 2001;32:2580-2586.
12. O'Connor FF, Shields DC, Fitzgerald A, Cannon CP, Braunwald E, Fitzgerald DJ: Genetic variation in glycoprotein IIb/IIIa (GPIIb/IIIa) as a determinant of the responses to an oral GPIIb/IIIa antagonist in patients with unstable coronary syndromes. Blood 2001;98:3256-3260.
13. Ardissino D, Mannucci PM, Merlini PA, Duca F, Fetiveau R, Tagliabue L, Tubaro M, Galvani M, Ottani F, Ferrario M, Corral J, Margaglione M: Prothrombotic genetic risk factors in young survivors of myocardial infarction. Blood 1999;94:46-51.
14. Szolnoki Z, Somogyvari F, Kondacs A, Szabo M, Fodor L: Evaluation of the interactions of common genetic mutations in stroke subtypes. J Neurol 2002;249:1391-1397.
15. Gerdes VE, ten Cate H, de Groot E, Kwa VI, Prins MH, Reitsma PH, Buller HR, Brandjes DP: Arterial wall thickness and the risk of recurrent ischemic events in carriers of the prothrombin G20210A mutation with clinical manifestations of atherosclerosis. Atherosclerosis 2002;163:135-140.
16. Wald DS, Law M, Morris JK: Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002;325:1202.
17. Kelly PJ, Rosand J, Kistler JP, Shih VE, Silveira S, Plomaritoglou A, Furie KL: Homocysteine, MTHFR 677C → T polymorphism, and risk of ischemic stroke: results of a metaanalysis. Neurology 2002;59:529-536.
18. Slooter AJ, Rosendaal FR, Tanis BC, Kemmeren JM, van der Graaf Y, Algra A: Prothrombotic conditions, oral contraceptives, and the risk of ischemic stroke. J Thromb Haemost 2005;3:1213-1217.
19. Standeven KF, Grant PJ, Carter AM, Scheiner T, Weisel JW, Ariens RA: Functional analysis of the fibrinogen Aalpha Thr312Ala polymorphism: effects on fibrin structure and function. Circulation 2003;107:2326-2330.
20. Uitte de Willige S, De Visser MC, Houwing-Duistermaat JJ, Rosendaal FR, Vos HL, Bertina RM: Genetic variation in the fibrinogen gamma gene increases the risk for deep venous thrombosis by reducing plasma fibrinogen gamma levels. Blood 2005;106:4176-4183.
21. Uitte de Willige S, Doggen CJ, De Visser MC, Bertina RM, Rosendaal FR: Haplotypes of the fibrinogen gamma gene do not affect the risk of myocardial infarction. J Thromb Haemost 2006;4:474-476.
22. Martiskainen M, Pohjasvaara T, Mikkelsson J, Mantyla R, Kunnas T, Laippala P, Ilveskoski E, Kaste M, Karhunen PJ, Erkinjuntti T: Fibrinogen gene promoter -455 A allele as a risk factor for lacunar stroke. Stroke 2003;34:886-891.
23. Smith FB, Connor JM, Lee AJ, Cooke A, Lowe GD, Rumley A, Fowkes FG: Relationship of the platelet glycoprotein PlA and fibrinogen T/G+1689 polymorphisms with peripheral arterial disease and ischaemic heart disease. Thromb Res 2003;112:209-216.
24. Reiner AP, Carty CL, Carlson CS, Wan JY, Rieder MJ, Smith JD, Rice K, Fornage M, Jaquish CE, Williams OD, Tracy RP, Lewis CE, Siscovick DS, Boerwinkle E, Nickerson DA: Association between patterns of nucleotide variation across the three fibrinogen genes and plasma fibrinogen levels: the Coronary Artery Risk Development in Young Adults (CARDIA) study. J Thromb Haemost 2006;4:1279-1287.
25. Jannes J, Hamilton-Bruce MA, Pilotto L, Smith BJ, Mullighan CG, Bardy PG, Koblar SA: Tissue plasminogen activator -7351C/T enhancer polymorphism is a risk factor for lacunar stroke. Stroke 2004;35:1090-1094.
26. Armstrong CA, Bevan SN, Gormley KT, Markus HS, Koblar SA: Tissue plasminogen activator -7351C/T polymorphism and lacunar stroke. Stroke 2006;37:329-330.
27. Austin H, Chimowitz MI, Hill HA, Chaturvedi S, Wechsler LR, Wityk RJ, Walz E, Wilterdink JL, Coull B, Sila CA, Mitsias P, Evatt B, Hooper WC: Cryptogenic stroke in relation to genetic variation in clotting factors and other genetic polymorphisms among young men and women. Stroke 2002;33:2762-2768.
28. Wiklund PG, Nilsson L, Ardnor SN, Eriksson P, Johansson L, Stegmayr B, Hamsten A, Holmberg D, Asplund K: Plasminogen activator inhibitor-1 4G/5G polymorphism and risk of stroke: replicated findings in two nested case-control studies based on independent cohorts. Stroke 2005;36:1661-1665.
29. Cipollone F, Toniato E, Martinotti S, Fazia M, Iezzi A, Cuccurullo C, Pini B, Ursi S, Vitullo G, Averna M, Arca M, Montali A, Campagna F, Ucchino S, Spigonardo F, Taddei S, Virdis A, Ciabattoni G, Notarbartolo A, Cuccurullo F, Mezzetti A: A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke. JAMA 2004;291:2221-2228.
30. Dai K, Gao W, Ruan C: The Sma I polymorphism in the von Willebrand factor gene associated with acute ischemic stroke. Thromb Res 2001;104:389-395.
31. Di Bitondo R, Cameron CL, Daly ME, Croft SA, Steeds RP, Channer KS, Samani NJ, Lillicrap D, Winship PR: The -1185 A/G and -1051 G/A dimorphisms in the von Willebrand factor gene promoter and risk of myocardial infarction. Br J Haematol 2001;115:701-706.
32. Baker RI, Eikelboom J, Lofthouse E, Staples N, Afshar-Kharghan V, Lopez JA, Shen Y, Berndt MC, Hankey G: Platelet glycoprotein Ibalpha Kozak polymorphism is associated with an increased risk of ischemic stroke. Blood 2001;98:36-40.
33. Ollikainen E, Mikkelsson J, Perola M, Penttila A, Karhunen PJ: Platelet membrane collagen receptor glycoprotein VI polymorphism is associated with coronary thrombosis and fatal myocardial infarction in middle-aged men. Atherosclerosis 2004;176:95-99.
34. Takagi S, Iwai N, Baba S, Mannami T, Ono K, Tanaka C, Miyata T, Miyazaki S, Nonogi H, Goto Y: A GPVI polymorphism is a risk factor for myocardial infarction in Japanese. Atherosclerosis 2002;165:397-398.
35. Cole VJ, Staton JM, Eikelboom JW, Hankey GJ, Yi Q, Shen Y, Berndt MC, Baker RI: Collagen platelet receptor polymorphisms integrin alpha2beta1 C807T and GPVI Q317L and risk of ischemic stroke. J Thromb Haemost 2003;1:963-970.
36. Ott I, Koch W, von Beckerath N, de Waha R, Malawaniec A, Mehilli J, Schomig A, Kastrati A: Tissue factor promotor polymorphism -603 A/G is associated with myocardial infarction. Atherosclerosis 2004;177:189-191.
37. Wang Y, Zhang W, Zhang Y, Yang Y, Sun L, Hu S, Chen J, Zhang C, Zheng Y, Zhen Y, Sun K, Fu C, Yang T, Wang J, Sun J, Wu H, Glasgow WC, Hui R: VKORC1 haplotypes are associated with arterial vascular diseases (stroke, coronary heart disease, and aortic dissection). Circulation 2006;113:1615-1621.
38. Kalaria RN: Advances in molecular genetics and pathology of cerebrovascular disorders. Trends Neurosci 2001;24:392-400.
39. Luyendijk W, Bots GT, van der Vegter V, Went LN, Frangione B: Hereditary cerebral haemorrhage caused by cortical amyloid angiopathy. J Neurol Sci 1988;85:267-280.
40. Chabriat H, Vahedi K, Iba-Zizen MT, Joutel A, Nibbio A, Nagy TG, Krebs MO, Julien J, Dubois B, Ducrocq X: Clinical spectrum of CADASIL: a study of 7 families - cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Lancet 1995;346:934-939.
41. Greenberg SM, Vonsattel JP, Segal AZ, Chiu RI, Clatworthy AE, Liao A, Hyman BT, Rebeck GW: Association of apolipoprotein E epsilon2 and vasculopathy in cerebral amyloid angiopathy. Neurology 1998;50:961-965.
42. Woo D, Kaushal R, Chakraborty R, Woo J, Haverbusch M, Sekar P, Kissela B, Pancioli A, Jauch E, Kleindorfer D, Flaherty M, Schneider A, Khatri P, Sauerbeck L, Khoury J, Deka R, Broderick J: Association of apolipoprotein E4 and haplotypes of the apolipoprotein E gene with lobar intracerebral hemorrhage. Stroke 2005;36:1874-1879.
43. Sazci A, Ergul E, Tuncer N, Akpinar G, Kara I: Methylenetetrahydrofolate reductase gene polymorphisms are associated with ischemic and hemorrhagic stroke: dual effect of MTHFR polymorphisms C677T and A1298C. Brain Res Bull 2006;71:45-50.
44. Algra A, De Schryver EL, van Gijn J, Kappelle LJ, Koudstaal PJ: Oral anticoagulants versus antiplatelet therapy for preventing further vascular events after transient ischaemic attack or minor stroke of presumed arterial origin. Cochrane Database Syst Rev 2006;3:CD001342.
45. CAPRIE Steering Committee: A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-1339.
46. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, Leys D, Matias-Guiu J, Rupprecht HJ: Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004;364:331-337.
47. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Brennan DM, Fabry-Ribaudo L, Booth J, Topol EJ: Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354:1706-1717.
48. Brown DL: Deaths associated with platelet glycoprotein IIb/IIIa inhibitor treatment. Heart 2003;89:535-537.
49. Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM, Rettie AE: Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002;287:1690-1698.
50. Lee CR, Goldstein JA, Pieper JA: Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in vitro and human data. Pharmacogenetics 2002;12:251-263.
51. Gage BF, Eby C, Milligan PE, Banet GA, Duncan JR, McLeod HL: Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb Haemost 2004;91:87-94.
52. Yin T, Miyata T: Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives. Thromb Res 2007;120:1-10.
53. Pruissen DM, Rosendaal FR, Gorter J, Garcia AA, Kappelle LJ, Algra A: Haemostatic genetic variants, ABO blood group and bleeding risk during oral anticoagulant treatment after cerebral ischaemia of arterial origin. J Neurol, Epub ahead of print.
54. Antithrombotic Trialists' Collaboration: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. BMJ 2002;324:71-86.
55. Tran HA, Anand SS, Hankey GJ, Eikelboom JW: Aspirin resistance. Thromb Res 2007;120:337-346.
56. Cattaneo M: Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol 2004;24:1980-1987.
57. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S: Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002;105:1650-1655.
58. Halushka MK, Walker LP, Halushka PV: Genetic variation in cyclooxygenase 1: effects on response to aspirin. Clin Pharmacol Ther 2003;73:122-130.
59. Lepantalo A, Mikkelsson J, Resendiz JC, Viiri L, Backman JT, Kankuri E, Karhunen PJ, Lassila R: Polymorphisms of COX-1 and GPVI associate with the antiplatelet effect of aspirin in coronary artery disease patients. Thromb Haemost 2006;95:253-259.
60. Hillarp A, Palmqvist B, Lethagen S, Villoutreix BO, Mattiasson I: Mutations within the cyclooxygenase-1 gene in aspirin non-responders with recurrence of stroke. Thromb Res 2003;112:275-283.
61. Kranzhofer R, Ruef J: Aspirin resistance in coronary artery disease is correlated to elevated markers for oxidative stress but not to the expression of cyclooxygenase (COX) 1/2, a novel COX-1 polymorphism or the PlA(1/2) polymorphism. Platelets 2006;17:163-169.
62. Maree AO, Curtin RJ, Chubb A, Dolan C, Cox D, O'Brien J, Crean P, Shields DC, Fitzgerald DJ: Cyclooxygenase-1 haplotype modulates platelet response to aspirin. J Thromb Haemost 2005;3:2340-2345.
63. Undas A, Sydor WJ, Brummel K, Musial J, Mann KG, Szczeklik A: Aspirin alters the cardioprotective effects of the factor XIII Val34Leu polymorphism. Circulation 2003;107:17-20.
64. Deckmyn H, Chew SL, Vermylen J: Lack of platelet response to collagen associated with an autoantibody against glycoprotein Ia: a novel cause of acquired qualitative platelet dysfunction. Thromb Haemost 1990;64:74-79.
65. Kehrel B, Balleisen L, Kokott R, Mesters R, Stenzinger W, Clemetson KJ, van de Loo J: Deficiency of intact thrombospondin and membrane glycoprotein Ia in platelets with defective collagen-induced aggregation and spontaneous loss of disorder. Blood 1988;71:1074-1078.
66. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Escaned J, Moreno R, Hernandez-Antolin R, Sabate M, Trabetti E, Pignatti PF, Macaya C: 807 C/T polymorphism of the glycoprotein Ia gene and pharmacogenetic modulation of platelet response to dual antiplatelet treatment. Blood Coagul Fibrinolysis 2004;15:427-433.
67. O'Connor FF, Shields DC, Fitzgerald A, Cannon CP, Braunwald E, Fitzgerald DJ: Genetic variation in glycoprotein IIb/IIIa (GPIIb/IIIa) as a determinant of the responses to an oral GPIIb/IIIa antagonist in patients with unstable coronary syndromes. Blood 2001;98:3256-3260.
68. De Schryver EL; European/Australian Stroke Prevention in Reversible Ischaemia Trial (ESPRIT) group: Design of ESPRIT: an international randomized trial for secondary prevention after non-disabling cerebral ischaemia of arterial origin. Cerebrovasc Dis 2000;10:147-150.
69. Simons PC, Algra A, van de Laak MF, Grobbee DE, van der Graaf Y: Second manifestations of ARTerial disease (SMART) study: rationale and design. Eur J Epidemiol 1999;15:773-781.
70. Pruissen DM, Kappelle LJ, Algra A: Polymorphisms and Risk of Ischemic Stroke (POLARIS) study: rationale and design. Eur Neurol 2004;51:30-34.
71. Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A: Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006;367:1665-1673.
72. The ESPRIT Study Group: Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial. Lancet Neurol 2007;6:115-124.
73. The ESPRIT Study Group: Classification of cause of death after stroke in clinical research. Stroke 2006;37:1521-1524.
74. Harrell FE Jr, Lee KL, Mark DB: Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996;15:361-387.
75. Steyerberg EW, Harrell FE Jr, Borsboom GJ, Eijkemans MJ, Vergouwe Y, Habbema JD: Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. J Clin Epidemiol 2001;54:774-781.
76. Dutch TIA Study Group: The Dutch TIA trial: protective effects of low-dose aspirin and atenolol in patients with transient ischemic attacks or nondisabling stroke. Stroke 1988;19:512-517.
77. Algra A: SPIRIT: new life spirit for anticoagulant treatment in the secondary prevention of brain infarcts? A new study - Stroke Prevention in Reversible Ischaemia Trial. Ned Tijdschr Geneeskd 1994;138:1037-1039.